Global Genetic Testing Market Size, Share, Opportunities, And Trends By Type (Prenatal Testing, New Born Screening, Diagnostic Testing, Carrier Testing, Predictive & Pre-symptomatic Testing), By Diseases (Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne’s Muscular Dystrophy, Alzheimer’s Diseases, Thalassemia, Huntington’s Disease, Others), By Technology (Introduction, Cyto-Genetics Testing, Biochemical Testing, Molecular Testing), And By Geography - Forecasts From 2025 To 2030

Genetic Testing Market Size:

The Global Genetic Testing Market is expected to grow from USD 14.904 billion in 2025 to USD 24.889 billion in 2030, at a CAGR of 10.80%.

The global genetic testing demand is driven by a number of factors such as the aging global population, rising incidences of genetic and hereditary diseases, growing awareness, technological advancements, and a rise in the application of genetic testing for the early detection of various diseases.

With the development of new technologies and innovation in both scientific research and research equipment, genetic testing is headed toward an era of high significance in the near future.  As investments in research and development related to genetic testing increase, the global genetic testing market is expected to witness a substantial boost in its overall growth in the next five years.

Genetic Testing Market Geographical Outlook:

North America holds the largest share in the global genetic testing market owing to technological advancements, the rising prevalence of genetic diseases, and the high quality of infrastructure to support the genetic testing industry in the region. However, emerging economies hold good potential for the growth of the genetic testing market due to factors such as a rising patient pool, more government funding supporting investment in the industry, and growing awareness regarding the technology. APAC region will witness the fastest market growth owing to the rising aging population, rising purchasing power, and technological advancements in the region. However, the high cost of genetic testing coupled with unclear reimbursement structure, lack of skilled personnel, and lack of regulations in the market will restrain the growth of this market during the forecast period.

Genetic Testing Market Research Methodology:

The report provides a brief introduction to the market and deals with detailed research methodology for calculating market size and forecasts, secondary data sources used, and the primary inputs which were taken for data validation. This section also outlines various segments which have been covered as part of the report.

Genetic Testing Market Dynamics:

The next section provides comprehensive market dynamics through an overview section along with growth drivers, challenges, and opportunities that exist in the current market. This section of the report also provides global and regional regulations that determine the market growth and industry value chain analysis of the genetic testing market. Complete industry analysis has also been covered by Porter’s five forces model as a part of this report section.

Genetic Testing Market Competitive Insight

The major players discussed in this report include F. Hoffmann-La Roche Ltd, 23&Me, Inc., Precipio, Inc., AutoGenomics, Abbott Laboratories, and Luminex Corporation among a few others.

Segmentation

The genetic testing market has been segmented by product type, diseases, technology, and geography:

• By Type
  • Prenatal Testing
  • New Born Screening
  • Diagnostic Testing
  • Carrier Testing
  • Predictive & Pre-symptomatic Testing
• By Diseases
  • Cancer
  • Cystic Fibrosis
  • Sickle Cell Anemia
  • Duchenne’s Muscular Dystrophy
  • Alzheimer’s Diseases
  • Thalassemia
  • Huntington’s Disease
  • Others
• By Technology
  • Cyto-genetics Testing
  • Biochemical Testing
  • Molecular Testing
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Others
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Others

---

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK 

5. GLOBAL GENETIC TESTING MARKET BY TYPE

5.1. Introduction

5.2. Prenatal Testing

5.3. New Born Screening

5.4. Diagnostic Testing

5.5. Carrier Testing

5.6. Predictive & Pre-symptomatic Testing

6. GLOBAL GENETIC TESTING MARKET BY DISEASE

6.1. Introduction

6.2. Cancer

6.3. Cystic Fibrosis

6.4. Sickle Cell Anemia

6.5. Duchenne’s Muscular Dystrophy

6.6. Alzheimer’s Disease

6.7. Thalassemia

6.8. Huntington’s Disease

6.9. Others

7. GLOBAL GENETIC TESTING MARKET BY TECHNOLOGY

7.1. Introduction

7.2. Cyto-genetics Testing

7.3. Biochemical Testing

7.4. Molecular Testing

7.5. Others

8. GLOBAL GENETIC TESTING MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil 

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Italy

8.4.5. Others

8.5. Middle East & Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. Australia

8.6.5. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. F. Hoffmann-La Roche Ltd

10.2. Abbott Laboratories

10.3. Precipio, Inc.

10.4. Ariosa Diagnostics, Inc.

10.5. Biocartis SA

10.6. Danaher Corporation

10.7. 23&Me, Inc.

10.8. DiaSorin

10.9. Labcorp

10.10. AutoGenomics 

10.11. Illumina, Inc 

10.12. Thermo Fisher Scientific

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

LIST OF FIGURES

LIST OF TABLES

Hoffmann-La Roche Ltd

Abbott Laboratories

Precipio, Inc.

Ariosa Diagnostics, Inc.

Biocartis SA

Danaher Corporation

23&Me, Inc.

DiaSorin

Labcorp

AutoGenomics 

Illumina, Inc 

Thermo Fisher Scientific